551 related articles for article (PubMed ID: 22025564)
21. Regulation of COX2 expression in mouse mammary tumor cells controls bone metastasis and PGE2-induction of regulatory T cell migration.
Karavitis J; Hix LM; Shi YH; Schultz RF; Khazaie K; Zhang M
PLoS One; 2012; 7(9):e46342. PubMed ID: 23029485
[TBL] [Abstract][Full Text] [Related]
22. Endocrine disrupting chemicals promote the growth of ovarian cancer cells via the ER-CXCL12-CXCR4 signaling axis.
Hall JM; Korach KS
Mol Carcinog; 2013 Sep; 52(9):715-25. PubMed ID: 22549810
[TBL] [Abstract][Full Text] [Related]
23. Concerted EP2 and EP4 Receptor Signaling Stimulates Autocrine Prostaglandin E
Mangelsen E; Rothe M; Schulz A; Kourpa A; Panáková D; Kreutz R; Bolbrinker J
Cells; 2020 May; 9(5):. PubMed ID: 32438662
[TBL] [Abstract][Full Text] [Related]
24. [Effects of chemokine receptor and its ligand on migration of ovarian cancer cells].
Li F; Zhu HS; Han ZQ; Chen G; Gao QL; Jia P; Zhang AL; Xi L; Xu Q; Liao GN; Wang SX; Lu YP; Ma D
Ai Zheng; 2005 Jan; 24(1):23-7. PubMed ID: 15642195
[TBL] [Abstract][Full Text] [Related]
25. CXCR7 is not obligatory for CXCL12-CXCR4-induced epithelial-mesenchymal transition in human ovarian cancer.
Zheng N; Liu W; Chen J; Li B; Liu J; Wang J; Gao Y; Shao J; Jia L
Mol Carcinog; 2019 Jan; 58(1):144-155. PubMed ID: 30259564
[TBL] [Abstract][Full Text] [Related]
26. Key role of the positive feedback between PGE(2) and COX2 in the biology of myeloid-derived suppressor cells.
Obermajer N; Kalinski P
Oncoimmunology; 2012 Aug; 1(5):762-764. PubMed ID: 22934275
[TBL] [Abstract][Full Text] [Related]
27. Chemokine axes CXCL12/CXCR4 and CXCL16/CXCR6 correlate with lymph node metastasis in epithelial ovarian carcinoma.
Guo L; Cui ZM; Zhang J; Huang Y
Chin J Cancer; 2011 May; 30(5):336-43. PubMed ID: 21527066
[TBL] [Abstract][Full Text] [Related]
28. Roles of prostaglandin E2-EP3/EP4 receptor signaling in the enhancement of lymphangiogenesis during fibroblast growth factor-2-induced granulation formation.
Hosono K; Suzuki T; Tamaki H; Sakagami H; Hayashi I; Narumiya S; Alitalo K; Majima M
Arterioscler Thromb Vasc Biol; 2011 May; 31(5):1049-58. PubMed ID: 21311040
[TBL] [Abstract][Full Text] [Related]
29. Targeting the CXCR4/CXCL12 axis in treating epithelial ovarian cancer.
Mao TL; Fan KF; Liu CL
Gene Ther; 2017 Oct; 24(10):621-629. PubMed ID: 28753202
[TBL] [Abstract][Full Text] [Related]
30. CXCR4 receptor blockage reduces the contribution of tumor and stromal cells to the metastatic growth in the liver.
Benedicto A; Romayor I; Arteta B
Oncol Rep; 2018 Apr; 39(4):2022-2030. PubMed ID: 29436696
[TBL] [Abstract][Full Text] [Related]
31. Green tea catechins reduce invasive potential of human melanoma cells by targeting COX-2, PGE2 receptors and epithelial-to-mesenchymal transition.
Singh T; Katiyar SK
PLoS One; 2011; 6(10):e25224. PubMed ID: 22022384
[TBL] [Abstract][Full Text] [Related]
32. Prostaglandin E2 promotes human CD34+ cells homing through EP2 and EP4 in vitro.
Wang Y; Lai S; Tang J; Feng C; Liu F; Su C; Zou W; Chen H; Xu D
Mol Med Rep; 2017 Jul; 16(1):639-646. PubMed ID: 28560401
[TBL] [Abstract][Full Text] [Related]
33. Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells.
Timoshenko AV; Xu G; Chakrabarti S; Lala PK; Chakraborty C
Exp Cell Res; 2003 Oct; 289(2):265-74. PubMed ID: 14499627
[TBL] [Abstract][Full Text] [Related]
34. Temporal expression of the PGE2 synthetic system in the kidney is associated with the time frame of renal developmental vulnerability to cyclooxygenase-2 inhibition.
Frölich S; Olliges A; Kern N; Schreiber Y; Narumiya S; Nüsing RM
Am J Physiol Renal Physiol; 2012 Jul; 303(2):F209-19. PubMed ID: 22573380
[TBL] [Abstract][Full Text] [Related]
35. Interleukin-1beta induces glycosaminoglycan synthesis via the prostaglandin E2 pathway in cultured human cervical fibroblasts.
Schmitz T; Leroy MJ; Dallot E; Breuiller-Fouche M; Ferre F; Cabrol D
Mol Hum Reprod; 2003 Jan; 9(1):1-8. PubMed ID: 12529415
[TBL] [Abstract][Full Text] [Related]
36. Selective inhibition of prostaglandin E2 receptors EP2 and EP4 modulates DNA methylation and histone modification machinery proteins in human endometriotic cells.
Arosh JA; Lee J; Starzinski-Powitz A; Banu SK
Mol Cell Endocrinol; 2015 Jul; 409():51-8. PubMed ID: 25843056
[TBL] [Abstract][Full Text] [Related]
37. CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer.
Righi E; Kashiwagi S; Yuan J; Santosuosso M; Leblanc P; Ingraham R; Forbes B; Edelblute B; Collette B; Xing D; Kowalski M; Mingari MC; Vianello F; Birrer M; Orsulic S; Dranoff G; Poznansky MC
Cancer Res; 2011 Aug; 71(16):5522-5534. PubMed ID: 21742774
[TBL] [Abstract][Full Text] [Related]
38. CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3/NF-κB/SDF-1α axis to enhance efficacy against pancreatic cancer.
Sun R; Sun Y; Wu C; Liu Y; Zhou M; Dong Y; Du G; Luo H; Shi B; Jiang H; Li Z
Mol Ther; 2023 Nov; 31(11):3193-3209. PubMed ID: 37735875
[TBL] [Abstract][Full Text] [Related]
39. [Effect of chemokine CXCL12 and its receptor CXCR4 on proliferation, migration and invasion of epithelial ovarian cancer cells].
Jiang YP; Wu XH; Xing HY; DU XY
Zhonghua Fu Chan Ke Za Zhi; 2007 Jun; 42(6):403-7. PubMed ID: 17697603
[TBL] [Abstract][Full Text] [Related]
40. CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells.
Gil M; Komorowski MP; Seshadri M; Rokita H; McGray AJ; Opyrchal M; Odunsi KO; Kozbor D
J Immunol; 2014 Nov; 193(10):5327-37. PubMed ID: 25320277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
